Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Key takeaways Eli Lilly has filed lawsuits against four telehealth companies—Mochi Health, Fella Health, Willow Health, and ...

Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...